Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 3/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451292 | 0.81 | BLM (0.46) | BLMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL13113891 | 0.81 | BLM (0.46) | BLMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL2763031 | 0.78 | BLM (0.43) | BLMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL3160546 | 0.76 | MEN1 (0.40) | MAPTMEN1KMT2ANPC1LMNA | |
| SCHEMBL27645340 | 0.74 | ATM (0.42) | KMT2ANPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL3163268 | 0.72 | MEN1 (0.39) | BLMMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4936881 | 0.71 | BLM (0.54) | BLMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL5545887 | 0.69 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL17025412 | 0.68 | BLM (0.51) | BLMMAPTMEN1KMT2ANPC1 | |
| Thioxanthene SCHEMBL10514224 | 0.66 | MEN1 (0.61) | BLMMAPTMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654257-B1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20090043091-A1 | Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090043091-A1 | Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090043091-A1 | Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7429660-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429660-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429660-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1654257-A1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-20050054657-A1 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| WO-2005016919-A1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043091-A1 | Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester | MYD88, MCL1, TLR1 | BLM 4699/4885MAPT 4311/4885MEN1 865/4885 |
| US-20050054657-A1 | ATM inhibitors | ATM, ATR, CHEK2 | BLM 64/4885MAPT 1236/4885MEN1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.